Multiomics Used To Stratify Multiple Myeloma Patients Into Affinity Groups
Alessandro Lagana, PhD, discusses his study with multiple myeloma patients now being assigned to one of 12 subgroups based on shared genetic and molecular features of their disease, one of the latest computational modeling tools being used to translate clinical data into better treatment decision-making in the clinic, and the first to apply multiomics to patients with the blood cancer.
Mount Sinai Researchers Discover Genes That Predict Good Response to Blood Cancer Therapy
Jun 16, 2022 View All Press ReleasesModel May Better Classify Multiple Myeloma and Relapse Risks
Jan 17, 2022 View All Press Releases
Scientists Identify New Types of a Blood Cancer and Potential Targeted Treatments
Nov 17, 2021 View All Press Releases